Nicole Golob-Schwarzl
Overview
Explore the profile of Nicole Golob-Schwarzl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
734
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zarfl M, Patra V, Bordag N, Quehenberger F, Golob-Schwarzl N, Gruber-Wackernagel A, et al.
Exp Dermatol
. 2024 Mar;
33(3):e15034.
PMID: 38459631
Polymorphic light eruption (PLE) has been mechanistically linked to cytokine abnormalities. Emerging preclinical evidence posits the skin microbiome as a critical modulator of ultraviolet (UV)-induced cytokine expression, thereby influencing subsequent...
2.
Krassnig S, Leber S, Orthmann A, Golob-Schwarzl N, Huber H, Wohlrab C, et al.
J Neurooncol
. 2023 Nov;
165(1):91-100.
PMID: 37907716
Purpose: Since glioma therapy is currently still limited until today, new treatment options for this heterogeneous group of tumours are of great interest. Eukaryotic initiation factors (eIFs) are altered in...
3.
Golob-Schwarzl N, Pilic J, Benezeder T, Bordag N, Painsi C, Wolf P
J Invest Dermatol
. 2023 Oct;
144(3):500-508.e3.
PMID: 37865179
Eukaryotic initiation factor 4E (eIF4E) has been known to play a critical role in the regulation of gene expression and essential cellular processes, such as proliferation, apoptosis and differentiation. In...
4.
Kendzia S, Franke S, Krohler T, Golob-Schwarzl N, Schweiger C, Toeglhofer A, et al.
Mol Cancer
. 2023 May;
22(1):89.
PMID: 37248468
Aim: Chemoresistance is a major cause of treatment failure in colorectal cancer (CRC) therapy. In this study, the impact of the IGF2BP family of RNA-binding proteins on CRC chemoresistance was...
5.
Golob-Schwarzl N, Schweiger C, Koller C, Krassnig S, Gogg-Kamerer M, Gantenbein N, et al.
Oncotarget
. 2023 Feb;
14:83-84.
PMID: 36745526
No abstract available.
6.
Blunder S, Brunner P, Hofbauer J, Golob-Schwarzl N, Bauer J, Kimeswenger S
J Dtsch Dermatol Ges
. 2022 Dec;
20(12):1680-1681.
PMID: 36508378
No abstract available.
7.
Regan J, Schumacher D, Staudte S, Steffen A, Lesche R, Toedling J, et al.
iScience
. 2022 Jun;
25(7):104498.
PMID: 35720265
Recent evidence demonstrates that colon cancer stem cells (CSCs) can generate neurons that synapse with tumor innervating fibers required for tumorigenesis and disease progression. Greater understanding of the mechanisms that...
8.
Golob-Schwarzl N, Woltsche N, Armento A, Wolf P, Horwath-Winter J, Wedrich A, et al.
Eye (Lond)
. 2022 Apr;
36(12):2353-2355.
PMID: 35428870
No abstract available.
9.
Krassnig S, Wohlrab C, Golob-Schwarzl N, Raicht A, Schatz C, Birkl-Toeglhofer A, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33807050
Glioblastoma (GBM) is an utterly devastating cerebral neoplasm and current therapies only marginally improve patients' overall survival (OS). The PI3K/AKT/mTOR pathway participates in gliomagenesis through regulation of cell growth and...
10.
Graier T, Golob-Schwarzl N, Weger W, Benezeder T, Painsi C, Salmhofer W, et al.
Front Med (Lausanne)
. 2021 Mar;
8:624462.
PMID: 33644099
SARS-Cov2 has raised concerns among dermatologists regarding psoriasis and its respective treatments. Comorbidities, which induce the expression of the proprotease furin have been associated with severe course of COVID-19. Furin...